- Home
- RLAY vs MIST Comparison
RLAY vs MIST Comparison
Compare RLAY & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- MIST
- Stock Information
- Founded
- RLAY 2015
- MIST 2003
- Country
- RLAY United States
- MIST Canada
- Employees
- RLAY N/A
- MIST N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- RLAY Health Care
- MIST Health Care
- Exchange
- RLAY Nasdaq
- MIST Nasdaq
- Market Cap
- RLAY 576.1M
- MIST 89.8M
- IPO Year
- RLAY 2020
- MIST N/A
- Fundamental
- Price
- RLAY $3.63
- MIST $1.94
- Analyst Decision
- RLAY Strong Buy
- MIST Strong Buy
- Analyst Count
- RLAY 11
- MIST 2
- Target Price
- RLAY $18.40
- MIST $7.50
- AVG Volume (30 Days)
- RLAY 1.6M
- MIST 566.2K
- Earning Date
- RLAY 08-05-2025
- MIST 08-07-2025
- Dividend Yield
- RLAY N/A
- MIST N/A
- EPS Growth
- RLAY N/A
- MIST N/A
- EPS
- RLAY N/A
- MIST N/A
- Revenue
- RLAY $7,679,000.00
- MIST N/A
- Revenue This Year
- RLAY $14.31
- MIST N/A
- Revenue Next Year
- RLAY N/A
- MIST N/A
- P/E Ratio
- RLAY N/A
- MIST N/A
- Revenue Growth
- RLAY N/A
- MIST N/A
- 52 Week Low
- RLAY $1.78
- MIST $0.63
- 52 Week High
- RLAY $10.72
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- RLAY 63.22
- MIST 65.73
- Support Level
- RLAY $3.10
- MIST $1.86
- Resistance Level
- RLAY $3.75
- MIST $1.97
- Average True Range (ATR)
- RLAY 0.23
- MIST 0.10
- MACD
- RLAY 0.03
- MIST 0.00
- Stochastic Oscillator
- RLAY 84.42
- MIST 80.00
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).